TransMedics Group (NASDAQ:TMDX) Stock Gets Price Target Increase from Stifel Nicolaus

TransMedics Group (NASDAQ:TMDX – Get Free Report) had its target price boosted by analysts at Stifel Nicolaus from $70.00 to $80.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus‘s price target indicates a potential downside of 6.16% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on TMDX. TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Barclays began coverage on shares of TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target on the stock. UBS Group raised their price target on shares of TransMedics Group from $77.00 to $88.00 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $73.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, TransMedics Group has a consensus rating of “Hold” and an average target price of $113.30.

Check Out Our Latest Stock Analysis on TransMedics Group

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $85.25 on Friday. The stock has a market cap of $2.96 billion, a P/E ratio of 23.10, a PEG ratio of 1.51 and a beta of 2.14. The stock has a 50 day simple moving average of $80.88 and a 200 day simple moving average of $90.94. The company has a current ratio of 4.53, a quick ratio of 4.15 and a debt-to-equity ratio of 1.46. TransMedics Group has a 1-year low of $60.10 and a 1-year high of $156.00.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. The firm had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The company’s revenue for the quarter was up 41.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.66 EPS. Research analysts anticipate that TransMedics Group will post 1.66 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction on Friday, September 11th. The stock was purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of TMDX. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in TransMedics Group in the third quarter valued at about $69,892,000. Dimensional Fund Advisors LP grew its stake in TransMedics Group by 5.5% during the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock worth $51,355,000 after buying an additional 26,969 shares in the last quarter. Braidwell LP grew its stake in TransMedics Group by 85.1% during the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after buying an additional 280,324 shares in the last quarter. Wellington Management Group LLP grew its stake in TransMedics Group by 6.1% during the second quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after buying an additional 29,500 shares in the last quarter. Finally, Congress Asset Management Co. increased its holdings in TransMedics Group by 11.0% in the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock valued at $21,109,000 after buying an additional 25,118 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.

Further Reading

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.